MarginsXMarginsX
Home › Markets › Health Care › PLX

Protalix BioTherapeutics Inc. (DE) (PLX)

PLX trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.03
-0.66% on the day
Market cap
$255.5M
Micro cap
Revenue · 2025
$52.7M
-1.2% on 2024
Net income · 2025
-$6.6M
-12.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1006281/000110465926029858/0001104659-26-029858-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerPLX on NYSE
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryIsrael
IPO yearNot reported by the screener
SEC CIK0001006281
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$52.7M
Net income-$6.6M
Operating income-$5.5M
Net margin-12.5%
Operating margin-10.4%
Revenue growth-1.2%
Cash$14.7M
Total assets$82.3M
P/E (computed)Net income was not positive
P/S (computed)4.8×

Warning signs

Cash runway
Cash-flow positive
$22.0M cash at September 30, 2026
Share count, 1 year
+4.8%
2025-11-01 to 2026-11-01 · +15.6% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
$101K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$22.0M cash; operating cash flow $4.4M a quarter.Report 2026-09-30
Shares outstanding84,318,923 (2026-11-01); 80,421,181 a year earlier; 72,952,124 three years earlier.Cover page 2026-11-01
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKesselman & Kesselman C.P.A.s, Tel-Aviv, IsraelPCAOB Form AP 2026-03-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $101K, sold $314 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$21.9M$4.0M$3.9M$22.0MNo debt tags$84.7M10-Q 2026-11-10
Q2 2026
2026-06-30
$19.9M$3.8M-$10.4M$27.4MNo debt tags$80.6M10-Q 2026-08-12
Q1 2026
2026-03-31
$33.8M$18.3M$22.0M$41.0MNo debt tags$76.4M10-Q 2026-05-13
Q4 2025
2025-12-31
$9.1M-$5.5M$2.0M$14.7MNo debt tags$52.7M10-K 2026-03-18
Q3 2025
2025-09-30
$17.9M$2.4M-$3.7M$13.6MNo debt tags$61.8M10-Q 2026-11-10
Q2 2025
2025-06-30
$15.7M$164K-$5.2M$17.9MNo debt tags$61.9M10-Q 2026-08-12
Q1 2025
2025-03-31
$10.1M-$3.6M-$5.1M$19.5MNo debt tags$59.8M10-Q 2026-05-13
Q4 2024
2024-12-31
$18.2M$6.5M$4.0M$19.8M$0$53.4M10-K 2026-03-18

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-08-22
Latest annual report10-K2026-03-18
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEF 14A2026-04-30

Source: SEC EDGAR submissions feed, 974 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+20.1%
1 month+10.9%
3 months+29.2%
Year to date+69.4%
1 year+58.0%
From 52-week high-3.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
OCGNOcugen Inc.$0.7730-6.62%$262.3M
LXEOLexeo Therapeutics Inc.$3.23+12.54%$265.0M
SABSSAB Biotherapeutics Inc.$3.00+1.35%$270.3M
CABACabaletta Bio Inc.$1.11-13.28%$239.4M
DTILPrecision BioSciences Inc.$7.28-3.77%$277.6M
ALLOAllogene Therapeutics Inc.$0.8070-3.78%$279.6M
AGENAgenus Inc.$6.29-6.54%$284.6M
EDITEditas Medicine Inc.$1.87-13.82%$288.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier